New daily pill MP-214 tested for Long-Term schizophrenia control

NCT ID NCT01625897

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the long-term safety and effectiveness of a new daily pill called MP-214 in 125 people with chronic or elderly schizophrenia. Participants took either MP-214 or the existing drug risperidone for several weeks. The goal was to see if MP-214 is a safe and tolerable option for managing schizophrenia over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MP-214 (a once-daily pill) compared with risperidone (another antipsychotic pill)
What this could lead to: If successful, MP-214 could offer a new long-term treatment option for managing schizophrenia symptoms.
What could go wrong: This is an early-to-mid-stage study with only 125 participants, so results may not apply to everyone. Side effects are possible, and the drug may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychiatric disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Aizu-Wakamatsu, Fukushima, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.